Skip to main content
S

Shenyang Xingqi Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 300573 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,229 across all filing types
Latest filing 2026-05-11 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300573

About Shenyang Xingqi Pharmaceutical Co., Ltd.

https://www.sinqi.com

Shenyang Xingqi Pharmaceutical Co., Ltd. specializes in the research, development, production, and sale of ophthalmic medications. The company provides a comprehensive portfolio of eye care solutions targeting conditions such as myopia, dry eye syndrome, glaucoma, and ocular infections. Key products include low-dose atropine sulfate eye drops for slowing myopia progression in children, cyclosporine eye drops for dry eye, and various anti-infective and anti-inflammatory agents. The firm operates advanced manufacturing facilities and maintains a robust R&D pipeline focused on innovative drug delivery systems and therapeutic treatments for vision health. By integrating clinical research with industrial production, the company serves as a major provider of specialized ophthalmic pharmaceuticals, addressing diverse clinical needs in the field of ophthalmology.

Recent filings

Filing Released Lang Actions
关于盐酸利多卡因眼用凝胶Ⅲ期临床试验取得临床试验总结报告的提示性公告
Regulatory Filings Classification · 75% confidence The document is a corporate announcement on the Shenzhen Stock Exchange about obtaining a Phase III clinical trial summary report for a drug. It contains no financial statements or dividend/capital structure details and is not requesting votes or reporting share transactions. It is an operational R&D update that does not fit specific categories like Earnings Release, M&A, Dividend, or Proxy materials. Therefore, it falls into the miscellaneous regulatory announcements category (fallback).
2026-05-11 Chinese
2025年度募集资金存放、管理与使用情况的专项报告
Capital/Financing Update Classification · 89% confidence The document is a detailed standalone report on the storage, management, and use of funds raised by the company in a prior equity issuance. It outlines amounts raised, allocations, project spending, and regulatory compliance for 2025—i.e., a comprehensive update on the company’s financing proceeds. This aligns directly with the Capital/Financing Update (CAP) category, rather than a simple publication notice or another report type.
2026-04-21 Chinese
非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 65% confidence The document is a standalone Chinese ‘非经营性资金占用及其他关联资金往来情况汇总表’ (Summary of non-operating fund occupation and related party transactions) approved by the board. It does not constitute a full annual or interim report, nor is it announcing publication of a report. It is a regulatory disclosure table required by securities exchange rules but falls under miscellaneous filings. Therefore, it is best classified under General Regulatory Filings (RNS).
2026-04-21 Chinese
2025年年度报告摘要
Annual Report Classification · 100% confidence The document is titled '沈阳兴齐眼药股份有限公司2025年年度报告摘要' (Shenyang Xingqi Pharmaceutical Co., Ltd. 2025 Annual Report Summary). It contains key financial data, management discussion, and operational highlights for the fiscal year 2025. While it is a 'summary' (摘要), in the context of Chinese A-share regulatory filings, the 'Annual Report Summary' is a standard, substantive disclosure document that provides the core financial and operational information required by the Shenzhen Stock Exchange, distinct from a mere announcement of the report's availability. Therefore, it is classified as an Annual Report (10-K). FY 2025
2026-04-21 Chinese
关于获得药品注册证书的公告
Regulatory Filings
2026-04-03 Chinese
关于获得药品注册证书的公告
Regulatory Filings
2026-03-27 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.